Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19229728 | 1.00 | JAK3 (0.38) | JAK3TEAD1JAK1EGFRITK | |
| SCHEMBL19229729 | 1.00 | JAK3 (0.38) | JAK3TEAD1JAK1EGFRITK | |
| SCHEMBL1628865 | 0.95 | JAK3 (0.41) | JAK3TEAD1JAK1EGFRITK | |
| SCHEMBL410336 | 0.95 | JAK3 (0.41) | JAK3TEAD1JAK1EGFRITK | |
| SCHEMBL1628867 | 0.95 | JAK3 (0.41) | JAK3TEAD1JAK1EGFRITK | |
| SCHEMBL14479237 | 0.88 | TEAD1 (0.40) | JAK3TEAD1BTK | |
| SCHEMBL1629421 | 0.88 | TEAD1 (0.40) | JAK3TEAD1BTK | |
| SCHEMBL1630022 | 0.88 | TEAD1 (0.40) | JAK3TEAD1BTK | |
| SCHEMBL24021438 | 0.83 | JAK3 (0.42) | JAK3JAK1EGFRITKBTK | |
| SCHEMBL19240691 | 0.83 | JAK3 (0.45) | JAK3JAK1EGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | JAK3 182/4885TEAD1 3282/4885JAK1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.